HE4 is a Beneficial Biomarker in Endometrial Cancer

NCT03459976 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 87

Last updated 2019-01-25

No results posted yet for this study

Summary

Evaluation of Serum level of Human Epididymis Secretory Protein 4 (HE4) in Endometrial Cancer and clinical significant it

Conditions

Interventions

DIAGNOSTIC_TEST

evaluate serum level HE4 in endometrial cancer

1. HE4 in beignin endometrial diseases 2. HE4 in endometrial cancer

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • M Elhafeez Assistant Professor Obstetrics and Gy, phD · Obstetrics and Gynecology

  • H Fathy Assistant Professor Obstetrics and Gy, phD · ASU

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2019-04-01
Completion
2019-04-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03459976 on ClinicalTrials.gov